Abeona Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission, disclosing financial results and operational updates for the second quarter of fiscal year 2026.
Key Highlights
- Shares outstanding: As of August 10, 2026, Abeona Therapeutics had 57,184,017 shares of common stock outstanding, according to the filing.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, as indicated on the cover page.
- Listed security: Common stock with a $0.01 par value trades under the symbol ABEO on the Nasdaq Capital Market (NASDAQ:ABEO).
- Commercialization focus: The filing cites the company's ability to "successfully commercialize ZEVASKYN and generate future revenue" as a key forward-looking subject addressed in the report.
- Pipeline item: The filing references the development of ABO-701 and the deprioritization of AAV-based ophthalmology programs as matters covered in the report.
- Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
Abeona Therapeutics' Q2 2026 Quarterly Report: ZEVASKYN, ABO-701, and Operating Status
Abeona Therapeutics Inc., headquartered at 6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103, filed its Form 10-Q for the quarterly period ended June 30, 2026. The filing covers financial statements, management's discussion and analysis, and other required disclosures for the three and six months ended June 30, 2026, compared against corresponding periods in 2025. The commission file number assigned to the registrant is 001-15771.
According to the filing, key subjects addressed in the report include the company's commercialization of ZEVASKYN, its sole approved product. The filing notes several manufacturing and commercial risks associated with ZEVASKYN, including the ability to "manufacture sufficient batches of ZEVASKYN to meet demand" and challenges tied to ZEVASKYN's "84-hour shelf-life before surgical application." The filing also states that the company's ability to recognize revenue depends on factors such as "qualified treatment centers obtaining biopsy samples from ZEVASKYN patients of sufficient quality to act as starting material for manufacturing ZEVASKYN."
The filing discloses that the company has deprioritized its AAV-based ophthalmology programs and references ongoing development of ABO-701, including efforts to "submit an investigational new drug application for ABO-701 and enroll patients in new clinical trials." The company's forward-looking statements, which the filing identifies as subject to risks and uncertainties described in its Risk Factors and MD&A sections, also address capital requirements, additional financing needs, and the potential dilutive effect of future equity sales. The filing attributes these as forward-looking statements that "speak only as of the date made and are not guarantees of future performance."
What Was Disclosed
Abeona Therapeutics submitted its quarterly report covering the period ended June 30, 2026, reporting 57,184,017 shares outstanding as of August 10, 2026, and addressing ZEVASKYN commercialization, ABO-701 development, and financing considerations as principal topics.



Please wait processing your request...